Eevia Health Plc

Stemtech Corporation received a proposal to acquire Eevia Health Oyj (NGM:EEVIA) in a reverse merger transaction on November 10, 2024. Stemtech Corporation signed a letter of intent to acquire Eevia Health in a reverse merger transaction on November 29, 2024. As on December 2, 2024, parties entered into an agreement. Under the proposed RTO, Eevia will acquire the assets and assume the liabilities of Stemtech and, upon completion of the Merger, VIÁGO by Eevia issuing new shares, resulting in Stemtech owning approximately 85% of Eevia, with the remaining 15% of the Eevia shares owned by its existing shareholders. The final valuation, share issuance, and terms are subject to conditions, including the negotiation of the definitive agreements, a third-party valuation, and the completion of the due diligence process. The final valuation, number of shares to be issued, and issue price are subject to negotiation and the due diligence process of both companies. The Board of Eevia plans to present the RTO to its shareholders during an Extraordinary General Meeting (EGM), which Eevia plans to promptly schedule. The approval of the proposed RTO will be contingent on regulatory compliance, including a new listing process on the Spotlight Stock Market, where Eevia is currently listed, the negotiation and execution of applicable definitive agreements and other appropriate conditions. Expected synergies created through these business combinations include streamlined costs and enhanced operational efficiency, that are expected to deliver significant positive impact on operations and profitability. Upon completion of these business combinations, the combined companies should be well positioned to increase market share in three high-growth sectors, leveraging a vast global network, and a proven track record. Stemtech Corporation cancelled the acquisition of Eevia Health Oyj (NGM:EEVIA) in a reverse merger transaction on December 12, 2024. After careful consideration and preliminary due diligence efforts, the Board of Directors of Eevia Health has decided that Evia Health Plc could not meet the deadlines necessary to make this RTO and has terminated the said letter of intent. The companies are now in negotiations to merge into a company listed on the Swedish MTF Nordic SME Sweden, a part of the Nordic Growth Market (NGM), though no definitive agreement has yet been executed. The proposed RTO will be subject to additional conditions, including an exemption from the obligation to make a bid from the Swedish Securities Council and compliance with other regulatory requirements, the negotiation and execution of definitive agreements, including mutually accepted representations, warranties and covenants. Raytelligence acted as advisor in this process.